Physician profile
Justin Schweitzer
NPI 1386894129
$1,987.82
in general payments reported to CMS, 2019-2025
14 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.09 · 2020: $48.91 · 2021: $157 · 2022: $273 · 2023: $796 · 2024: $301 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734 · Consulting Fee: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.79 |
| Consulting Fee | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $700.00 | 2023 | Kxl System (Not Refurbished) |
| Viiv Healthcare Company | $378.09 | 2023-2025 | Apretude |
| Gilead Sciences, INC. | $266.78 | 2021-2025 | |
| Abbvie INC. | $179.00 | 2021-2023 | |
| Allergan, INC. | $161.99 | 2021-2022 | |
| Exact Sciences Corporation | $59.58 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $55.53 | 2024-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Pfizer INC. | $51.46 | 2019-2020 | |
| Quidel Corporation | $34.29 | 2020 | |
| Abbott Laboratories | $24.57 | 2019 | |
| Hologic Sales and Service, LLC | $24.04 | 2024 | Aptima |
| Becton, Dickinson and Company | $21.86 | 2025 | Bd Onclarity |
| Lilly USA, LLC | $16.95 | 2024 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Schweitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.